Topic
Topic
A 48-week real-world retrospective study on Springer Nature Link tracks lebrikizumab in atopic dermatitis patients who switched from dupilumab or tralokinumab. Effectiveness data pending full publica…
Lebrikizumab sustained skin clearance and itch reduction in atopic dermatitis across four years of follow-up, per HCPLive's long-…
Two moderate-to-severe atopic dermatitis patients in Mexico improved on lebrikizumab in routine practice, per a Cureus case repor…
Selective IL-13 inhibition with lebrikizumab showed benefit in pediatric atopic dermatitis, per a new medical reference summary f…
Eli Lilly's EBGLYSS label update from the FDA allows one subcutaneous maintenance dose every eight weeks for adults with moderate…
Phase 3 data show lebrikizumab improved atopic dermatitis symptoms and itch in children, extending IL-13 inhibition evidence into…
Eli Lilly's Ebglyss cleared or nearly cleared hand and foot eczema in 53% of patients versus 27% on placebo, per Medical Daily, f…
Lebrikizumab maintains improvements in itch and lesions for up to five years in moderate-to-severe atopic dermatitis, extending t…
Lilly reports Phase 3b data showing EBGLYSS (lebrikizumab-lbkz) achieved significant, rapid improvements in skin clearance, itch,…
Phase 3b trial data show lebrikizumab improves hand and foot atopic dermatitis, giving clinicians trial-based evidence in a hard-…
